NSCLC (MET Exon 14) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About NSCLC (MET Exon 14)
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and within it, there are various subtypes. One such subtype is characterized by a specific genetic alteration known as a MET exon 14 skipping mutation. This mutation leads to an overactive MET protein, which drives uncontrolled cancer cell growth. Identifying this particular mutation is crucial because it allows for highly targeted treatment approaches, moving away from a one-size-fits-all strategy.
Diagnosing NSCLC MET exon 14 involves molecular testing of tumor tissue or blood samples. If this mutation is found, patients are often candidates for targeted therapies specifically designed to inhibit the MET protein. Common medications approved for this condition include oral medications like capmatinib (Tabrecta), tepotinib (Tepmetko), and savolitinib. These drugs work by blocking the abnormal MET signaling, helping to shrink tumors and slow disease progression. While these targeted therapies can be highly effective, they are also specialty medications, often coming with a substantial price tag, creating financial strain for patients and their families.
This is where TheDrugClub steps in. We believe that no one should have to choose between their health and their finances. For just
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.